A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors

Inclusion Criteria: * Patients with advanced malignancy diagnosed histologically and/or cytologically, who have failed standard treatment or are unable to receive standard treatment or have no effective treatment. * Age: 18\~75 years old. * Women of childbearing age must be negative for serum or urine HCG within 7 days prior to study enrollment and must be non-lactating; Patients should agree to use contraception during the study period and for 6 months after the study period. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Life expectancy ≥ 3 months. * Patients voluntarily joined the study and signed the informed consent, showing good compliance. Exclusion Criteria: * Patients has had or is currently having other malignant tumors within 3 years. * Patients have multiple factors that affect their oral medication (such as inability to swallow, chronic diarrhea, and intestinal obstruction). * The patient had unmitigated toxic reactions due to any prior treatment. * Patients underwent major surgical treatment, open biopsy, or significant traumatic injury within 4 weeks prior to the start of study treatment. * Patients have long-term unhealed wounds or fractures. * The patient had experienced an arterial/venous thrombosis event in the past 6 months, such as a cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis, and pulmonary embolism. * The patient has a history of psychotropic drug abuse and cannot quit or has mental disorders. * Patients are taking cytochrome P450 3A (CYP3A) inhibitors or inducers. * Patients have uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage. * Patients with brain metastases with symptoms or control of symptoms for less than 2 weeks. * The patients were currently breastfeeding or planned to breastfeed during the study period. * Patients who, in the investigator's judgment, have a comorbidity that seriously endangers patient safety or interferes with study completion, or who are considered unsuitable for inclusion for other reasons